Teva price target raised to $28 from $25 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps an Overweight rating on the shares. The firm says Duvakitug with a 27% delta clinical remission for ulcerative colitis and 35% delta endoscopic response for Crohn’s disease reflects a best in class efficacy profile. The data further validate Teva’s pivot to growth strategy, the analyst tells investors in a research note.